Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Dr. Lal PathLabs's OCF Margin % or its related term are showing as below:
NSE:LALPATHLAB'
s OCF Margin % Range Over the Past 10 Years
Min: 18.16 Med: 22.01 Max: 25.18
Current: 21.99
During the past 13 years, the highest OCF Margin % of Dr. Lal PathLabs was 25.18%. The lowest was 18.16%. And the median was 22.01%.
NSE:LALPATHLAB's OCF Margin % is ranked better than 80.3% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.53
vs NSE:LALPATHLAB: 21.99
The historical data trend for Dr. Lal PathLabs's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a OCF Margin % of 0.00% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Dr. Lal PathLabs and its competitors. Over the past decade, Dr. Lal PathLabs' OCF Margin % has ranged from 18.16 to 25.18. According to the industry distribution chart, Dr. Lal PathLabs ranks #40 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 19.7%.
Is Dr. Lal PathLabs' OCF Margin % too high?
Dr. Lal PathLabs' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 18.16 to a high of 25.18. Based on the distribution chart, Dr. Lal PathLabs ranks #40 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #40 out of 203 companies for OCF Margin %. This places Dr. Lal PathLabs in the top 20% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.53. Historically, Dr. Lal PathLabs' own OCF Margin % has ranged from 18.16 to 25.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 5.53, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current OCF Margin % is 0.00%. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current OCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
OCF Margin %: 0.00%
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
